futibatinib

Futibatinib is an investigational targeted therapy drug that has been studied for its potential in treating certain types of cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors. Specifically, futibatinib targets fibroblast growth factor receptors (FGFRs), which are proteins that play a role in cell growth and development. In some cancers, FGFRs can become overactive or mutated, promoting the uncontrolled proliferation of cancer cells.

Research has focused on futibatinib's efficacy in cancers that harbor specific FGFR alterations, such as cholangiocarcinoma, a type of bile duct cancer. Clinical trials have evaluated futibatinib's ability to block the signaling pathways driven by these altered FGFRs, aiming to inhibit tumor growth and induce cancer cell death. The drug is administered orally.

The development of futibatinib is part of a broader effort to personalize cancer treatment by targeting the molecular drivers of specific tumors. While promising results have emerged from early-stage studies, futibatinib is still undergoing clinical evaluation to determine its full therapeutic potential, optimal dosage, and safety profile in various cancer types and patient populations.